BioNxt Solutions Inc. (BNXT) | WebDisclosure

Basculer en Français

8299	Companies
114948	Keywords
55352	Articles
62471	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

PRESS RELEASE

published on 07/09/2024 at 09:05, 4 months 12 days ago

BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization
BioNxt Solutions Inc. signs master services agreement with German-based CRDMO for product development of oral dissolvable drug formulations

BioNxt Solutions Inc. Product Development Master Services Agreement CRDMO Oral Dissolvable Drug Formulations
BRIEF

published on 06/20/2024 at 01:05, 5 months 1 day ago

BioNxt Solutions clôture la deuxième tranche de placement privé

Placement Privé Actions Ordinaires Bons De Souscription Financement De La Recherche Solutions BioNxt
BRIEF

published on 06/20/2024 at 01:05, 5 months 1 day ago

BioNxt Solutions Closes Second Tranche of Private Placement

Private Placement Common Shares Warrants Research Funding BioNxt Solutions
PRESS RELEASE

published on 06/20/2024 at 01:00, 5 months 1 day ago

BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement
BioNxt Solutions Inc. closes the second tranche of non-brokered private placement, raising $270,000. Proceeds will fund research, development, and working capital

Private Placement Common Shares Working Capital Research And Development BioNxt Solutions Inc.
BRIEF

published on 04/26/2024 at 05:55, 6 months 25 days ago

BioNxt Solutions fait progresser les études sur la cladribine et annonce une initiative de financement

Placement Privé BioNxt Solutions Inc. Sclérose En Plaques Programme Cladribine Développement Pharmaceutique
BRIEF

published on 04/26/2024 at 05:55, 6 months 25 days ago

BioNxt Solutions Advances Cladribine Studies and Announces Financing Initiative

Private Placement BioNxt Solutions Inc. Multiple Sclerosis Cladribine Program Pharmaceutical Development
PRESS RELEASE

published on 04/26/2024 at 05:50, 6 months 25 days ago

Bionxt Solutions Announces Odf Cladribine Update and Financing
BioNxt Solutions Inc. advances Cladribine program to human bioavailability studies in Europe, targeting MS market. Announces private placement for research and development

Private Placement BioNxt Solutions Inc. Cladribine Program Bioavailability Studies Multiple Sclerosis Market
BRIEF

published on 03/18/2024 at 08:10, 8 months 3 days ago

BioNxt Advances Towards Human Trials with ODF Cladribine for MS

Clinical Trials BioNxt Solutions Inc. Multiple Sclerosis Drug Delivery Technology Pharmaceutical Market
BRIEF

published on 03/18/2024 at 08:10, 8 months 3 days ago

BioNxt progresse vers des essais sur l'homme avec la cladribine ODF pour le traitement de la SEP

BioNxt Solutions Inc. Essais Cliniques Sclérose En Plaques Technologie D'administration De Médicaments Marché Pharmaceutique
PRESS RELEASE

published on 03/18/2024 at 08:05, 8 months 3 days ago

BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
BioNxt Solutions Inc. reports progress in toxicity and PK studies, advancing towards human comparative bioavailability studies. Development includes technology transfer, upscaling, & clinical sample prep for bioequivalence study

BioNxt Solutions Inc. Toxicity Studies Comparative Pharmacokinetic Studies Bioavailability Pharmaceutical Drug Market

Accesswire

Published on 11/21/2024 at 14:30, 24 minutes ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Published on 11/21/2024 at 14:30, 24 minutes ago

Sarama Announces Equity Placement of Up to A$2M and Issue of Equity for Debt
Published on 11/21/2024 at 14:15, 39 minutes ago

neurocare Group AG Welcomes Kevin Reeder as Chief Financial Officer
Published on 11/21/2024 at 14:00, 54 minutes ago

Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 54 minutes ago

Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 14:16, 38 minutes ago

EQS-Adhoc: LM PAY S.A. Announces Third Quarter 2024 Preliminary Results and Updated Guidance
Published on 11/21/2024 at 14:15, 39 minutes ago

ZenaTech Signs Blue UAS and NDAA Compliant Supply Chain Partners to Sell to US Defense Branches and NATO Forces
Published on 11/21/2024 at 14:00, 54 minutes ago

Form 8.3 - LOYS AG: Learning Technologies Group plc
Published on 11/21/2024 at 13:41, 1 hour 13 minutes ago

Original-Research: Pentixapharm Holding AG (von BankM AG): Kaufen
Published on 11/21/2024 at 13:15, 1 hour 39 minutes ago

NOTICE OF ANNUAL GENERAL MEETING

Les Echos

Published on 11/21/2024 at 06:58, 7 hours 56 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 7 hours 56 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 7 hours 56 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 18 hours 47 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 19 hours 34 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE